Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Matsukawa W et al. | Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. | 1992 | J. Lab. Clin. Med. | pmid:1371298 |
Sampson BA and Gotschlich EC | Neisseria meningitidis encodes an FK506-inhibitable rotamase. | 1992 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1371354 |
Andersson J et al. | Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. | 1992 | Immunology | pmid:1371491 |
Strasser S et al. | Effect of FK506 on insulin secretion in normal dogs. | 1992 | Metab. Clin. Exp. | pmid:1371575 |
Andersson J et al. | FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. | 1992 | Transplant. Proc. | pmid:1371621 |
Matsuura T et al. | Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. | 1992 | Transplant. Proc. | pmid:1371623 |
Okamura N et al. | Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. | 1992 | Transplant. Proc. | pmid:1371624 |
Sakr M et al. | Effect of renal ischemia on plasma levels of FK 506 in rats. | 1992 | Transplant. Proc. | pmid:1371625 |
Taormina D et al. | Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. | 1992 | Am J Hosp Pharm | pmid:1373936 |
Ochiai T | [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. | 1992 | Arerugi | pmid:1374229 |
Hung DT and Schreiber SL | cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1374240 |
Jayaraman T et al. | FK506 binding protein associated with the calcium release channel (ryanodine receptor). | 1992 | J. Biol. Chem. | pmid:1374404 |
Höllsberg P et al. | Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. | 1992 | J. Immunol. | pmid:1374452 |
Schreiber SL and Crabtree GR | The mechanism of action of cyclosporin A and FK506. | 1992 | Immunol. Today | pmid:1374612 |
Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
Bundick RV et al. | FK506 as an agonist to induce inhibition of interleukin 2 production. | 1992 | Transplantation | pmid:1374947 |
Ogasa N et al. | Successful transplantation of newborn rat intestine as a free graft. | 1992 | Transplant. Proc. | pmid:1376514 |
Graeb C et al. | Cytoimmunologic monitoring of small bowel allograft recipients. | 1992 | Transplant. Proc. | pmid:1376515 |
Date K et al. | Effect of FK 506 on graft survival in rat small intestinal allografts. | 1992 | Transplant. Proc. | pmid:1376516 |
Hatazawa C et al. | Effect of FK 506 on bowel transplantation in rats. | 1992 | Transplant. Proc. | pmid:1376517 |
Jain A et al. | Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. | 1992 | Transplant. Proc. | pmid:1376518 |
Masutani H et al. | Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. | 1992 | Transplant. Proc. | pmid:1376519 |
Santiago SF et al. | Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. | 1992 | Transplant. Proc. | pmid:1376520 |
Utsunomiya H et al. | Effect of FK 506 on orthotopic small bowel transplantation in rats. | 1992 | Transplant. Proc. | pmid:1376521 |
Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
Yagihashi A et al. | HLA matching effect in liver transplantation. | 1992 | Transplant. Proc. | pmid:1281569 |
Kobayashi M et al. | Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. | 1992 | Transplant. Proc. | pmid:1281570 |
Lemster B et al. | Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. | 1992 | Transplant. Proc. | pmid:1281576 |
Tze WJ et al. | FK 506: an effective immunosuppressant for islet xenotransplantation. | 1992 | Transplant. Proc. | pmid:1281577 |
Kamei T et al. | Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. | 1992 | Transplant. Proc. | pmid:1281579 |
Woo J et al. | FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. | 1992 | Transplant. Proc. | pmid:1281583 |
Ramamoorthy S et al. | Selective impairment of taurine transport by cyclosporin A in a human placental cell line. | 1992 | Pediatr. Res. | pmid:1378960 |
Armitage JM et al. | Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. | 1992 | Ann. Thorac. Surg. | pmid:1379032 |
Thomson AW | The spectrum of action of new immunosuppressive drugs. | 1992 | Clin. Exp. Immunol. | pmid:1379130 |
Fischer G et al. | Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. | 1992 | Mol. Microbiol. | pmid:1379319 |
Rondeau E | [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin]. | 1992 | Nephrologie | pmid:1379348 |
Schreiber SL | Immunophilin-sensitive protein phosphatase action in cell signaling pathways. | 1992 | Cell | pmid:1379518 |
Aldape RA et al. | Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. | 1992 | J. Biol. Chem. | pmid:1379588 |
Langrehr JM et al. | Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. | 1992 | J. Clin. Invest. | pmid:1379617 |
First MR | Renal transplantation for the nephrologist: new immunosuppressive drugs. | 1992 | Am. J. Kidney Dis. | pmid:1371201 |
Bach JF | Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. | 1992 | J. Autoimmun. | pmid:1380245 |
Baumann G et al. | Molecular mechanisms of immunosuppression. | 1992 | J. Autoimmun. | pmid:1380246 |
Walpoth B et al. | Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. | 1992 | Eur Surg Res | pmid:1380460 |
Petros AM et al. | Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. | 1992 | FEBS Lett. | pmid:1380470 |
Van Thiel DH et al. | FK 506 reduces the injury experienced following renal ischemia and reperfusion. | 1992 | Ren Fail | pmid:1380720 |
Bolton C | The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). | 1992 | Agents Actions | pmid:1380765 |
Terada N et al. | Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1380801 |
Dhar DK et al. | The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. | 1992 | Transplantation | pmid:1384188 |
Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
Meiser BM et al. | Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. | 1992 | Transplant. Proc. | pmid:1384201 |
Wakabayashi H et al. | Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. | 1992 | Transplant. Proc. | pmid:1384205 |
Griffin AD et al. | FK 506 in canine renal transplantation. | 1992 | Transplant. Proc. | pmid:1384209 |
Griffiths RJ et al. | Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. | 1992 | Agents Actions | pmid:1384284 |
Todo S et al. | Intestinal transplantation in composite visceral grafts or alone. | 1992 | Ann. Surg. | pmid:1384443 |
Massol N et al. | Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1384470 |
Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
Arai S et al. | The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. | 1992 Jul-Aug | J. Heart Lung Transplant. | pmid:1379829 |
Fagiuoli S et al. | FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. | 1992 Jul-Aug | Ital J Gastroenterol | pmid:1381245 |
Tong J et al. | Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. | 1992 Jul-Aug | Haematologica | pmid:1385279 |
Nazer H et al. | FK 506 associated disorders in liver transplantation. | 1992 May-Jun | J. Gastroenterol. Hepatol. | pmid:1377038 |
Bowman H and Lennard TW | Immunosuppressive drugs. | 1992 Nov 4-17 | Br J Hosp Med | pmid:1282440 |
Sattler M et al. | Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. | 1992 Sep-Oct | Drug Metab. Dispos. | pmid:1385058 |
Tabasco-Minguillan J et al. | Long-term insulin requirement after liver transplantation with FK 506 in American veterans. | 1993 | Transplant. Proc. | pmid:7679839 |
Klintmalm GB et al. | Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. | 1993 | Transplant. Proc. | pmid:7679840 |
Gunji Y et al. | Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. | 1993 | Transplant. Proc. | pmid:7679841 |
Gregory CR et al. | Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. | 1993 | Transplant. Proc. | pmid:7679842 |
Jayaraman T and Marks AR | Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. | 1993 | J. Biol. Chem. | pmid:7503980 |
D'Ambrosio R et al. | Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. | 1993 | Ther Drug Monit | pmid:7504339 |
Reese JC et al. | The effect of FK506 on canine bile flow. | 1993 | Transplantation | pmid:7504342 |
Valdivia LA et al. | Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. | 1993 | Transplantation | pmid:7681230 |
Fujimura A et al. | Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. | 1993 | Jpn. J. Pharmacol. | pmid:7681489 |
Nishinaka Y et al. | Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. | 1993 | J. Cardiovasc. Pharmacol. | pmid:7681507 |
Luan S et al. | Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. | 1993 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7681590 |
Mühl H et al. | Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. | 1993 | Eur. J. Pharmacol. | pmid:7506668 |
Simek SL et al. | Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. | 1993 | Genomics | pmid:7507077 |
Izumi S and Okuhara M | [FK506 and kifunensine, new immunomodulators of microbial origin]. | 1993 | Tanpakushitsu Kakusan Koso | pmid:7692469 |
Wakugami T et al. | Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. | 1993 | Tohoku J. Exp. Med. | pmid:7692621 |
Hill CC et al. | Penile prosthesis surgery in the immunosuppressed patient. | 1993 | Transplantation | pmid:7692633 |
Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
Sato M et al. | FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells. | 1993 | Acta Endocrinol. | pmid:7509103 |
Clipstone NA and Crabtree GR | Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509131 |
Blaehr H et al. | Acute effects of FK506 and cyclosporine A on cultured human proximal tubular cells. | 1993 | Eur. J. Pharmacol. | pmid:7683267 |
Kadmon M et al. | Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. | 1993 | Gastroenterology | pmid:7683296 |
Denesyuk AI et al. | Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7683466 |
Waschulewski IH et al. | Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. | 1993 | Br. J. Pharmacol. | pmid:7683567 |
Moutabarrik A et al. | Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. | 1993 | Transplant. Proc. | pmid:7685949 |
Takaya S et al. | Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. | 1993 | Transplant. Proc. | pmid:7685953 |
Murphy MP and Morris RE | Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. | 1993 | Transplant. Proc. | pmid:7685955 |
Yamaoka K et al. | Cyclosporin A and FK506 block the negative signaling mediated by surface IgM cross-linking in normal human mature B cells. | 1993 | Immunol. Lett. | pmid:7688712 |
Smith DF et al. | Two FKBP-related proteins are associated with progesterone receptor complexes. | 1993 | J. Biol. Chem. | pmid:7688746 |
Jacobs JC et al. | Pyoderma gangrenosum in infancy. | 1993 | J. Am. Acad. Dermatol. | pmid:7688775 |
Garrity GM et al. | Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. | 1993 | J. Ind. Microbiol. | pmid:7688970 |
Mollison KW et al. | Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689812 |
Tai PK et al. | P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. | 1993 | Biochemistry | pmid:7689858 |
Lieberman R | FK506, artificial intelligence and pharmacoeconomics. | 1993 | J Clin Pharmacol | pmid:7690045 |
McMichael J et al. | An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. | 1993 | J Clin Pharmacol | pmid:7690046 |
Armitage JM et al. | Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. | 1993 | J. Thorac. Cardiovasc. Surg. | pmid:7679172 |
Ito K and Komatsu Y | [Drug induced hemolytic uremic syndrome]. | 1993 | Nippon Rinsho | pmid:7679450 |
Langrehr JM et al. | Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. | 1993 | Transplantation | pmid:7679526 |